AB0457 Clinical equivalence in efficacy between abp 501 and adalimumab in patients with moderate to severe rheumatoid arthritis: a tipping point sensitivity analysis
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.6855
Abstract: Background ABP 501 is the first approved biosimilar to adalimumab. Patient withdrawals from clinical trials can result in missing data, which may lead to loss of statistical power and bias of the treatment difference estimate.… read more here.
Keywords: amgen inc; tipping point; point sensitivity; abp 501 ... See more keywords
AB0405 ADALIMUMAB THERAPEUTIC DRUG MONITORING TEST VALIDATED FOR MEASURING ABP 501 BIOSIMILAR
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.2360
Abstract: Background Promonitor-ADL test is routinely used to monitor IBD patients treated with adalimumab (ADL). ABP 501 (adalimumab biosimilar; Amgen) was authorised throughout the European Union in March 2017 and has been recently launched in several… read more here.
Keywords: promonitor adl; drug; abp 501; employee ... See more keywords
Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response—Data from the German HS Registry HSBest
Sign Up to like & getrecommendations! Published in 2022 at "Life"
DOI: 10.3390/life12101518
Abstract: Since 2021, adalimumab biosimilar ABP 501 can be used alternatively to adalimumab originator (ADAO) in the treatment of hidradenitis suppurativa (HS). Effectiveness and safety data remain scarce. We investigated the impact of switching from ADAO… read more here.
Keywords: adalimumab originator; registry; hidradenitis suppurativa; originator ... See more keywords